Kinnate Biopharma Inc.

Kinnate Biopharma Inc. (KNTE) priced its initial public offering on Dec 3, 2020 at $20.00 per share, above its $18.00–$19.00 range, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $830.5M. Goldman Sachs was lead-left underwriter, joined by Leerink Partners, Piper Sandler and Wedbush. Wilson Sonsini advised the company and Cooley advised the underwriters.

Kinnate Biopharma Inc. is a biopharmaceutical company discovering and developing small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. It focuses on patients whose cancers have known drivers without targeted therapies, intrinsic treatment resistance, or acquired resistance, using its Kinnate Discovery Engine.

Status

IPO

Ticker

KNTE

Exchange

Nasdaq Global Select

Priced

Dec 3, 2020

IPO price

$20.00

Price range

$18.00–$19.00

Market cap at IPO price

$830.5M

First filed

Nov 13, 2020

Underwriters

Goldman Sachs, Leerink Partners, Piper Sandler and Wedbush

Company counsel

Wilson Sonsini

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.